- Home
- UAN vs ABVX Comparison
UAN vs ABVX Comparison
Compare UAN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- ABVX
- Stock Information
- Founded
- UAN 2007
- ABVX 2013
- Country
- UAN United States
- ABVX France
- Employees
- UAN N/A
- ABVX N/A
- Industry
- UAN Agricultural Chemicals
- ABVX
- Sector
- UAN Industrials
- ABVX
- Exchange
- UAN Nasdaq
- ABVX Nasdaq
- Market Cap
- UAN 710.0M
- ABVX 722.3M
- IPO Year
- UAN 2011
- ABVX N/A
- Fundamental
- Price
- UAN $72.20
- ABVX $9.50
- Analyst Decision
- UAN
- ABVX Strong Buy
- Analyst Count
- UAN 0
- ABVX 6
- Target Price
- UAN N/A
- ABVX $36.50
- AVG Volume (30 Days)
- UAN 42.4K
- ABVX 82.3K
- Earning Date
- UAN 10-28-2024
- ABVX 09-09-2024
- Dividend Yield
- UAN 9.24%
- ABVX N/A
- EPS Growth
- UAN N/A
- ABVX N/A
- EPS
- UAN 4.97
- ABVX N/A
- Revenue
- UAN $527,388,000.00
- ABVX $9,676,417.00
- Revenue This Year
- UAN N/A
- ABVX $31.67
- Revenue Next Year
- UAN N/A
- ABVX $1,189.66
- P/E Ratio
- UAN $14.55
- ABVX N/A
- Revenue Growth
- UAN N/A
- ABVX 100.87
- 52 Week Low
- UAN $60.50
- ABVX $8.75
- 52 Week High
- UAN $88.94
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- UAN 59.13
- ABVX 34.50
- Support Level
- UAN $67.44
- ABVX $10.27
- Resistance Level
- UAN $72.22
- ABVX $10.79
- Average True Range (ATR)
- UAN 2.57
- ABVX 0.36
- MACD
- UAN 0.46
- ABVX -0.05
- Stochastic Oscillator
- UAN 76.85
- ABVX 8.16
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.